# A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms

> **NCT02842229** · — · COMPLETED · sponsor: **Celgene** · enrollment: 117 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Leukemia Myeloid Acute
- Multiple Myeloma
- Leukemia, Lymphocytic, Chronic, B-Cell

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02842229
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-20
- **Primary completion:** 2017-02-02
- **Final completion:** 2017-02-02
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2017-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02842229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02842229, "A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02842229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*